Eidos Therapeutics

$94.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.24 (+2.42%) As of 1:19 PM EST today

Why Robinhood?

You can buy or sell EIDX and other stocks, options, and ETFs commission-free!

About EIDX

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. The listed name for EIDX is Eidos Therapeutics, Inc. Common Stock.

CEO
Neil Kumar
Employees
45
Headquarters
San Francisco, California
Founded
2013
Market Cap
3.68B
Price-Earnings Ratio
Dividend Yield
Average Volume
158.19K
High Today
$95.78
Low Today
$92.78
Open Price
$92.78
Volume
31.27K
52 Week High
$96.13
52 Week Low
$28.39

Collections

EIDX Earnings

-$0.79
-$0.47
-$0.14
$0.18
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 24, After Hours

You May Also Like